AtlasInfectionsNeglected tropical diseases and malaria

Ebola

4Curable or preventable in mostAI-generated
Burden-over-time charts — how many people this disease affects and whether that number is rising or falling — are coming to this page. The treatability read, milestones, and live trial pipeline below are current.

Milestones

dot size = significance
199020002010202020252019 — Vesicular stomatitis virus encoding ebola virus glycoprotein approved (FDA)2020 — Maftivimab approved (FDA)2020 — Odesivimab approved (FDA)2020 — Atoltivimab approved (FDA)2020 — Adenovirus type 26 encoding ebola virus glycoprotein approved (FDA)2020 — Vaccinia virus, modified encoding ebola virus glycoprotein and nucleoprotein approved (FDA)2020 — Ansuvimab approved (FDA)
2019: Drug approval — Vesicular stomatitis virus encoding ebola virus glycoprotein approved (FDA). 2020: Drug approval — Maftivimab approved (FDA). 2020: Drug approval — Odesivimab approved (FDA). 2020: Drug approval — Atoltivimab approved (FDA). 2020: Drug approval — Adenovirus type 26 encoding ebola virus glycoprotein approved (FDA). 2020: Drug approval — Vaccinia virus, modified encoding ebola virus glycoprotein and nucleoprotein approved (FDA). 2020: Drug approval — Ansuvimab approved (FDA)

What's being tested now

2019: 1 trials started2024: 1 trials started2025: 2 trials started2026: 2 trials started202020262

Trials started per year, stacked by phase (darker = later phase). Source: ClinicalTrials.gov via Clin2, which tracks studies recruiting in recent years — early years undercount.

See all 7 active Ebola Virus Disease trials on Clin2 →

Related

Burden estimates: IHME Global Burden of Disease Study. Drug indications: ChEMBL (CC BY-SA). Trial data: ClinicalTrials.gov via Clin2. Velocity, acceleration, and turning points are computed by Clin2 — how this page is made. Treatability describes what medicine can do, not what is available everywhere. This page describes populations, not people, and is not medical advice.